Bausch & Lomb Incorporated
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bausch & Lomb Incorporated sits in the top decile of US sponsors by registered trial count (#170 of 15,742 sponsors by registered trial count).
Bausch & Lomb Incorporated: 174 sponsored US clinical trials, 3 recruiting.
Bausch & Lomb Incorporated sponsors 174 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 158 completed. 60 of these trials are in Phase 3-4 (later-stage) and 42 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myopia, with 9 trials.
Top-decile sponsor footprint
Bausch & Lomb Incorporated ranks in the top decile of sponsors by registered trial count (#170 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
158 of 166 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
174 total, page 3 of 4
A Study to Evaluate the Performance of Two Designs of Soft Toric Lenses
NCT01309867
Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
NCT01277341
Evaluation of the Feasibility a New Silicone Hydrogel Contact Lens
NCT01309906
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
NCT01230125
Product Feasibility of a New Silicone Hydrogel Contact Lens
NCT01309100
Study of A New Contact Lens Cleaning and Disinfecting Solution
NCT01318577
One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction
NCT01230060
Study to Evaluate a Contact Lens Lubricating and Rewetting Drop
NCT01267656
Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses
NCT01241279
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
NCT01212471
A Study to Evaluate the Product Performance of a Daily Disposable Contact Lens
NCT01192126
Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome
NCT01163643
Toric Intraocular Lens Following Cataract Surgery
NCT01140477
Evaluation of 3 Intraocular Lenses Following Lens Extraction
NCT01122576
Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
NCT01175590
Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
NCT01174823
Evaluation of Two Different Designs of Bausch & Lomb Contact Lenses
NCT01118338
Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
NCT01222299
Feasibility of a New Silicone Hydrogel Lens
NCT01131130
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
NCT01573572
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
NCT01107405
A Study to Assess the Safety and Efficacy of a Daily Disposable Contact Lens
NCT01130974
Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
NCT01060072
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
NCT00770133
Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
NCT01010633
A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution
NCT01024751
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
NCT00972777
Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers
NCT00985231
Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
NCT00905450
Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation
NCT00905762
Study of T-PRED(TM) Compared to Pred Forte(R) II
NCT00854061
Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects
NCT00824070
Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
NCT00853970
A Product Performance Evaluation of a Novel Contact Lens for Daily Disposable Use
NCT00784641
One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens
NCT00902850
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.
NCT00769886
Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease
NCT00758784
Evaluation of a Multi-Purpose Solution
NCT00710879
Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
NCT00699153
Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
NCT00704418
Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
NCT00703781
Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
NCT00705159
Study of T-PRED(TM) Compared to Pred Forte(R)
NCT00699803
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
NCT00667004
Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose Solution
NCT00636363
Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery
NCT00645671
Performance of Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution in a New Packaging Configuration
NCT00659815
Comparative Performance of PureVision, Acuvue Oasys and O2Optix
NCT00640341
Efficacy and Safety of Bromfenac Ophthalmic Solution
NCT00585975
Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
NCT00586664
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 26 |
| Phase 3 | 46 |
| Phase 4 | 14 |
Therapeutic Areas
What is open in the Bausch & Lomb Incorporated pipeline
3 recruiting of 174 indexed (2% open); 158 completed (91%).
Phase mix: 60 late (III/IV) vs 42 early (I/II) (balanced across stages).
Top condition: Myopia (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bausch & Lomb Incorporated: open-pipeline peers nationwide
Peers matched on 174 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Bausch & Lomb Incorporated sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 174 trials (± recruiting share)
- Albert Einstein College of Medicine · 175 trials · 11% recruiting
- UConn Health · 178 trials · 11% recruiting
- Tufts Medical Center · 169 trials · 11% recruiting
- Baylor Research Institute · 180 trials · 17% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Medtronic Cardiac Rhythm and Heart Failure · 2% recruiting · 115 trials
- Eisai · 2% recruiting · 287 trials
- Lexicon Pharmaceuticals · 2% recruiting · 56 trials
- Alcon Research · 2% recruiting · 275 trials
Related
What to do with this Bausch & Lomb Incorporated page
174 registered trials is a research-attention snapshot, not an endorsement of Bausch & Lomb Incorporated or any single study.
- 3 of Bausch & Lomb Incorporated's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Myopia is the condition Bausch & Lomb Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myopia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bausch & Lomb Incorporated pipeline card: 174 registered trials from official public datasets.Report a data error.